Navigation Links
Replidyne Phase II Pediatric Trial Meets Primary Objective

LOUISVILLE, Colo., March 06, 2007 /PRNewswire-FirstCall/ -- Replidyne, Inc. announced today that it has completed its Phase II clinical trial using faropenem medoxomil (faropenem) in pediatric patients with acute otitis media (AOM), a common infection of the middle ear. Initial analyses of the study results show that it met its primary objective to show that faropenem was effective in eradicating pathogens from the middle ear and to permit the dose selection for Phase III trials in AOM.

The study of over 300 pediatric patients examined four different doses of faropenem, administered twice daily as an oral suspension, and demonstrated a dose response in bacteriological eradication. All doses examined were well tolerated and there was no clear dose effect to tolerability. The trial included a double tap design where middle ear fluid is obtained both prior to and during treatment then submitted for culture. These cultures provide microbiologic documentation of faropenem's effectiveness in eradicating bacteria from the middle ear fluid.

"We are pleased with the positive results and rich bacteriological and clinical data generated from this study, and look forward to presenting these data in more detail at an upcoming scientific conference," said Kenneth J. Collins, Replidyne's President and CEO. "The results give us confidence that we will be able to select an appropriate dose for Phase III studies. We plan to meet with the FDA in the second quarter to share these data and discuss Phase III trial design for faropenem in pediatric AOM."

About Faropenem

Faropenem is a member of the penem subclass within the beta-lactam class of antibiotics. Beta-lactams are generally characterized by their favorable safety and tolerability profiles, as well as their broad spectrum of activity, and as a result are often used as first line therapy in many respiratory and skin infections in adult and pediatri
'"/>




Page: 1 2 3

Related medicine technology :

1. Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Replidyne Phase Pediatric Trial Meets Primary Objective
(Date:5/21/2013)... 21, 2013  NxStage Medical, Inc. (Nasdaq: ... today announced that it has entered into new agreements ... products to DaVita, the kidney care division of DaVita Healthcare ... For the use of products for home ... NxStage has executed a second amended and restated National ...
(Date:5/21/2013)... May 21, 2013 Valeant ... VRX ) (TSX: VRX) today announced ... at its 2013 annual meeting of ... the vote for the election of ... H. Farmer235,731,9341,964,748Robert A. Ingram233,865,8763,830,806Theo Melas-Kyriazi237,081,508615,174G. Mason ...
(Date:5/21/2013)... EAST TAUNTON, Massachusetts , 21. Mai ... Synergy Inc. („OSI"), die die Firmen OMNIlife ... ihren Tochtergesellschaften zählt, hat zwei neue, erfahrene ... Guy Mayer , eine erfahrene Führungspersönlichkeit ... Vorstandsvorsitzenden übernehmen. David Johnson ...
Breaking Medicine Technology:NxStage Announces New Agreements with DaVita 2Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 2Orthopaedic Synergy Inc. meldet bedeutenden Zuwachs im Vorstand 3
... NEW YORK, Nov. 17 Romeo and Juliette ... laser hair removal center in New York City to own ... a leading developer and manufacturer of laser and light-based aesthetic ... Cynosure,s patented MultiPlex sequencing technology, is a highly versatile laser ...
... , , SAN CLEMENTE, Calif., Nov. ... child between the ages of two through 12 are ... this coming winter, according to a survey conducted by ... company pioneering clinical research of natural remedies including Sinupret® ...
Cached Medicine Technology:Romeo and Juliette Laser Hair Removal Is First Center in New York City to Own Cynosure's New Elite MPX(TM) Laser System 2Survey Finds Mothers Take Children's Health Into Their Own Hands 2Survey Finds Mothers Take Children's Health Into Their Own Hands 3Survey Finds Mothers Take Children's Health Into Their Own Hands 4
(Date:5/22/2013)... , , TUESDAY, May 21 (HealthDay News) -- The overall ... in 10 people either overweight or obese and large ... or not exercising, a new government report shows. , ... Control and Prevention, the report found Americans continuing to ... to soaring rates of heart disease, diabetes and other ...
(Date:5/22/2013)... Teams who focus on productivity, process, quality, ... Do-Done StepTracker whiteboard as a rallying point for project ... display the current status of our company-wide lean initiatives ... is listed down the side and the milestones are ... squares are filled with yellow circles. Turning the magnets ...
(Date:5/22/2013)... Paris, France: Results from a large observational ... whether bivalirudin is superior to heparin in ... 30-day mortality in patients with non-ST segment ... coronary intervention (PCI)., European and US NSTE-ACS ... alternative to unfractionated heparin plus GP IIb/IIIa ...
(Date:5/22/2013)... 22, 2013 The PreDiabetes Center ... in the Greater Philadelphia Tour de Cure, a premier cycling ... are passionate about stopping the spread of diabetes , ... , The Tour de Cure will take place Saturday, ... Road in Ambler, 30 minutes outside of Philadelphia, between the ...
(Date:5/22/2013)... New York City, New York (PRWEB) May 22, 2013 ... Black American: Causes, Culture, Consequences, and Cost ” article published ... on obesity is fully justified. The Centers for Disease ... of U.S. adults aged 20 and over are overweight, 35.7% ... alarming facts are highlighted in this investigative article. In particular, ...
Breaking Medicine News(10 mins):Health News:Americans Still Making Unhealthy Choices: CDC 2Health News:Americans Still Making Unhealthy Choices: CDC 3Health News:Project Managers Organize Manufacturing Projects and Training with the New Steptracker Project Status Magnetic Whiteboards 2Health News:Registry questions superiority of bivalirudin over heparin 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 2Health News:PreDiabetes Centers to Appear at the Philadelphia Tour de Cure 3Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 2Health News:Black American Obesity Examined In The Latest FinancesOnline.com Article 3
... a mechanism by which an enzyme regulates gene expression ... someday lead to more effective drugs to attack cancers ... serious type of skin cancer, is highly resistant to ... understood. New research at VCU suggests that an enzyme ...
... the like keeps rising, U.S. government report shows , THURSDAY, ... steep rise in U.S. emergency department visits by people abusing ... new report finds. , In fact, between 2004 and 2008 ... 111 percent overall, and a whopping 29 percent during 2007-2008 ...
... , ... study shows overall reduction in medication expenses , ... Westerville, Ohio (PRWEB) June 17, 2010 -- Progressive Medical, ... The report reveals changes in medication spending on workers’ compensation claims from 2008 to ...
... INDIANAPOLIS Investments in the future of health care ... Health information technology (health IT) specialists are critical. ... want to offer their patients the benefits of electronic ... nationwide shortage of highly skilled health IT workers to ...
... an effort to protect children from harmful tobacco smoke exposure, ... smoking in public housing in a report appearing in this ... shows that those living in multiple-unit housing are being exposed ... lead author and pediatrician at MassGeneral Hospital for Children (MGHfC). ...
... Daylight ... day of summer – celebrates the many great, natural benefits daylight provides. , ... (PRWEB) June 17, 2010 ... to work, school, or issues that keep people indoors, bringing the sun into homes ...
Cached Medicine News:Health News:Researchers identify key enzyme in melanoma cell development 2Health News:ER Visits Soaring for Prescription Painkiller Misuse 2Health News:ER Visits Soaring for Prescription Painkiller Misuse 3Health News:Progressive Medical Releases 2010 Workers' Compensation Drug Spend Analysis 2Health News:IU and Regenstrief address critical need for health IT professionals 2Health News:Puffing in public housing poses serious health risks to tenants 2Health News:Puffing in public housing poses serious health risks to tenants 3Health News:Celebrate the First Day of Summer on Daylight Appreciation Day, June 21 2Health News:Celebrate the First Day of Summer on Daylight Appreciation Day, June 21 3
EnTrust family of ICDs provides a suite of features for total AT/AF co-morbidity management, including diagnostics to detect when your patient develops AT/AF, and both termination and intervention th...
... Medical is the world leader in ... used worldwide for permanent pacemaker and ... and port implantation, and for temporary ... St. Jude Medical Peel-Away introducers includes ...
... Stent System combines low-profile, high radial force, and ... wire compatible stent system provides 6F sheath / ... - 10.0 mm). Now, with longer stents available, ... stent lengths (28, 38, 56, 80 and 100 ...
... transseptal left heart catheterization occurs when the ... a sheath with an alternate curve while ... an exchange has required a repeat septal ... has overcome this problem with the unique ...
Medicine Products: